Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors while in the central anxious system, conolidine modulates alternate molecular targets. A Science Improvements research observed that conolidine interacts With all the atypical chemokine receptor ACKR3/C